Novel Concepts and Technologies in Vaccine Development for Emerging Pathogens
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: 31 March 2025 | Viewed by 41
Special Issue Editors
Interests: host–pathogen interaction; flavivirus; PAMPs; innate immunity; antiviral response; live attenuated vaccines; antigen design and production; host-targeted antiviral
Special Issues, Collections and Topics in MDPI journals
Interests: host–pathogen interaction; flavivirus; innate immunity; antiviral response; immunometabolism
Special Issue Information
Dear Colleagues,
Vaccination remains one of the most effective strategies for preventing and controlling infectious diseases. Due to biotechnological and molecular techniques, vaccine antigen production has realized significant advancements. This Special Issue aims to compile cutting-edge research and reviews focusing on innovative methods and technologies for producing antigens used in vaccination. We invite original research articles and comprehensive reviews on the following topics: recombinant protein antigens, peptide-based vaccines, DNA and RNA vaccines, virus-like particles (VLPs) and adjuvant development.
We invite researchers and practitioners from academia and industry to submit original research articles, comprehensive reviews and insightful commentaries notably on the following topics:
- Recombinant Protein Antigens:
- Expression systems (bacterial, yeast, insect, mammalian);
- Optimizing yield and purity;
- Post-translational modifications and their impact on immunogenicity.
- Peptide-Based Vaccines:
- Design and synthesis of peptide antigens;
- Enhancing stability and immunogenicity;
- Delivery systems for peptide vaccines.
- DNA and RNA Vaccines:
- Design and optimization of nucleic acid sequences;
- Delivery mechanisms (e.g., lipid nanoparticles, electroporation);
- Case studies and clinical trials.
- Virus-Like Particles (VLPs):
- Production and characterization of VLPs;
- Applications in vaccine development;
- Scalability and manufacturing challenges.
- Adjuvant Development:
- Novel adjuvants to enhance antigen efficacy;
- Mechanisms of action and safety profiles;
- Combining adjuvants with different types of antigens.
Dr. Wildriss Viranaicken
Dr. Grégorie Lebeau
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- virus-like particles
- DNA and RNA vaccines
- peptide-based vaccine
- expression system
- delivery system
- adjuvant
